Two indications.
One film. One pilot.
Project Lucid is the first clinical program testing a sublingual esketamine film with PTSD as the primary indication and autoimmune disease as an adjunctive indication — from a single Phase 1/2 pilot. 505(b)(2) pathway confirmed. LTS Lohmann GMP manufacturing active. Human PK established. IRB-ready, Q4 2026 enrollment.
What it is, who it helps, and why it's a two-shots-on-goal asset.
- The drug. 50mg sublingual esketamine film (LTS Lohmann). Bioequivalent Cmax to Spravato 56–84mg intranasal with a metabolite profile favoring synaptogenesis over dissociation.
- The two indications. PTSD primary ($3.5B market, no biologic holds the label) + autoimmune adjunctive ($120B market, same cytokines as Skyrizi / Cosentyx / Humira).
- Why one trial. PTSD patients carry 2× the autoimmune-disease burden (O'Donovan 2015, N=666,269). Wellington 2025 proved oral ketamine modulates IL-17, IFN-α/β, and cytokine-storm pathways in PTSD. One pilot reads out on both.
- The regulatory path. 505(b)(2) confirmed by FDAMap. Anchors to Spravato's safety package — no new animal tox. At-home delivery unlocked via non-inferiority vs. the Spravato REMS using validated digital monitoring.
- The defensible label. Flexible-dose tiles (25/50/75/100/125/150mg) within one product — a Phase 3 differentiator grounded in ketamine's inverted-U dose response.
- The ask. $2.5M SAFE on $12M pre-money cap. Funds Phase 1/2 (N=12), expanded biomarker panel, at-home REMS concordance dataset, and IND filing.
- The exit. Series A $15–25M post Phase 1 (Q4 2027); strategic interest from generic esketamine holders (Teva) and immunology-shelf acquirers on autoimmune signal. Transcend (MDMA analog) sold for ~$1.2B.
- The team. Richard Idell, MD — Dallas psychiatrist, Sponsor-Investigator. Advisors: Mukesh Kumar (FDAMap, 150+ trials); Steven Idell (40y NIH, Lung Therapeutics acquired); EMMES CRO; Neurolivd (patient voice).
The window has never been wider — and the cleanest lane is open.
The post-Lykos landscape has re-prioritized psychiatric assets with clean, placebo-controlled evidence packages. Ketamine's RCT record in PTSD is exactly that. No approved biologic holds the PTSD primary indication. No novel mechanism has been approved in 25 years. And oral ketamine is the first oral NMDA antagonist with transcriptomic evidence of modulating the same cytokines as the immunology shelf's top sellers.
Pre-IND seed SAFE
Series A target $15–25M post-Phase 1 (Q4 2027). Check size and subscription details on request. Dual funding path: non-dilutive DoD/VA grants (CDMRP TBIPHRP up to $2.1M; NIMH SBIR) pursued alongside equity.
Everything an analyst needs in one place.
Open documents for review. For full access including financial model, protocol redline, IP file, and IND readiness memo, contact investors@lucidptsd.com.
Built by operators with regulatory scars.
Where the $2.5M goes — and what it buys.
This round funds the Phase 1/2 pilot end-to-end, the expanded biomarker panel, the at-home REMS concordance dataset, and IND filing. Allocation is modeled against EMMES CRO quotes and benchmarked against comparable N=12 pre-IND pilots.
What this round delivers.
At the end of the 18-month runway, the company has produced the four assets a Series A investor will underwrite:
- A primary-endpoint CAPS-5 readout with pre-specified tipping-point robustness.
- A transcriptomic / cytokine biomarker dataset on the only oral-ketamine cohort ever collected in PTSD with autoimmune comorbidity.
- An at-home digital monitoring concordance dataset benchmarked against the Spravato REMS standard.
- A filed 505(b)(2) IND, anchored to the Spravato safety package — no new animal tox required.
Five inflection points between seed and Series A.
Each milestone below materially re-rates the asset. Investors entering at the seed SAFE are positioned ahead of all five.
Phase 1 PK complete. 505(b)(2) pathway confirmed by FDAMap. LTS GMP manufacturing active. 66-page IRB-ready protocol. PCT filed.
$12M pre-money capCentral IRB clearance de-risks regulatory and operational path. Drug supply, investigator site, CRO all executing.
Execution de-riskedIndependent safety review at N=3 and N=6. O'Brien-Fleming early-efficacy boundary (p<0.0054) lets a strong signal surface at interim.
Safety signal publicFull N=12 CAPS-5 result plus tipping-point robustness plus exploratory biomarker & REMS concordance data. The value inflection.
Primary catalyst505(b)(2) IND submission. Phase 2 RCT design (N=60–80) with integrated at-home monitoring arm. Series A raise to power the pivotal.
Series A $15–25MTiming targets reflect protocol and CRO schedules; actual calendar depends on IRB turnaround, site activation, and enrollment velocity.
What's already proven, what this round proves next, what remains.
The Project Lucid thesis stacks on top of an unusual amount of prior art — an FDA-approved parent product, a validated manufacturing platform, and a confirmed regulatory pathway. The remaining unknowns are small, defined, and directly addressed by this raise.
Before a dollar of this round is spent
- ✓Parent-product safety. Spravato (esketamine) approved 2019; the 505(b)(2) pathway inherits that package — no new animal tox.
- ✓Human PK established. Dahan 2022 characterized the 50mg SL OTF at Cmax ~96 ng/mL (comparable to Spravato 56–84mg).
- ✓GMP manufacturing active. LTS Lohmann thin-film platform in commercial production.
- ✓FDA regulatory pathway confirmed. 505(b)(2) viability signed off by FDAMap (Dr. Mukesh Kumar, 150+ trials).
- ✓Protocol IRB-ready. LUCID-PTSD-2026-001 v3.0 (66 pages), 4-member DSMB including rheumatologist.
- ✓IP position. PCT filed April 2026 after three U.S. provisionals; FTO confirmed.
- ✓CRO engaged. EMMES Corporation contracted for Phase 1/2.
What $2.5M produces by Q4 2027
- →PTSD efficacy for this formulation. CAPS-5 reduction with pre-specified tipping-point robustness on N=12.
- →At-home REMS non-inferiority dataset. HR/SpO₂ concordance ≥0.70 and CADSS remote sensitivity ≥90% vs. in-clinic — the prerequisite for an at-home label.
- →Exploratory neuroimmune biomarker signal. IL-17, IFN-α/β, TNF-α, IL-6 trajectories in PTSD patients with autoimmune comorbidity — bridging Wellington 2025 transcriptomics.
- →Long-term tolerability at 3×/week schedule. 4-week dosing cadence matched to Feder 2021 RCT protocol.
- →Filed 505(b)(2) IND. Type B pre-IND meeting, CMC package, IB bridging to Spravato.
- →Phase 2 RCT design. N=60–80 with integrated at-home monitoring arm, ready for Series A capital.
What a Series A investor underwrites next
- •Phase 2 efficacy at scale. Standard pharma risk; mitigated by 3×/week Feder protocol replicated at N=60–80.
- •REMS waiver at NDA. At-home label requires FDA signoff on the concordance package produced in Phase 1/2.
- •Commercial scale-out. Telehealth network, reimbursement, prescriber adoption — addressed post-NDA.
- •Competition. No approved PTSD biologic holds the primary indication; no novel mechanism approved in 25 years; post-Lykos no direct at-home competitor.
- •Autoimmune mechanism. Exploratory arm only — not a go/no-go, not bet on for Phase 2 design or Series A valuation.
How the market values assets in this corridor.
The investable space around Project Lucid has both approved-product economics (Spravato) and recent strategic transactions in the psychedelic / NMDA corridor. Project Lucid enters at a pre-IND seed valuation below each of these reference points.
FDA-approved esketamine nasal spray for treatment-resistant depression. Same molecule. In-clinic REMS. Project Lucid targets the same reimbursement tier (~$64K/patient/yr) with an at-home delivery moat and the PTSD primary label.
MDMA-analog PTSD program (methylone). Acquired by atai Life Sciences at ~$1.2B implied value. Psychiatric / trauma indication, novel mechanism — the closest recent strategic comp for a PTSD-focused NMDA / psychedelic asset.
Scientific advisor Dr. Steven Idell's prior company. Pulmonary-fibrosis franchise developed to Phase 2, acquired into Rein Therapeutics (NASDAQ). Demonstrated path from academic translational science to public-market exit.
Skyrizi (IL-23), Cosentyx (IL-17A), Humira (TNF-α) — the same cytokines modulated by oral ketamine in Wellington 2025 transcriptomics. The pricing corridor is 4× a psychiatric label; Project Lucid is not pricing here, but the mechanism overlap is the exploratory biomarker thesis.
FDA rejection of MDMA-assisted therapy (Aug 2024) removed the leading novel-mechanism PTSD candidate. Ketamine's placebo-controlled RCT record (Feder 2021, d=1.13) is the evidence shape the agency has asked for.
Teva (generic esketamine holder), J&J (Spravato franchise), and immunology-shelf acquirers all have strategic overlap. An at-home esketamine label with a placebo-controlled PTSD dataset is a clean bolt-on for each.
Precedents are reference points, not guarantees. Deal economics reflect public reporting and may include earn-outs, milestones, or contingent value. Project Lucid is an investigational candidate; no outcome is assured.
A qualified intake — faster than an email thread.
Share your firm, stage, and check size. Dr. Idell replies within one business day. All submissions are confidential and routed directly to investors@lucidptsd.com.
Let's talk.
Thirty minutes to walk through the thesis, the evidence, and the ask. If we're the wrong fit for your fund, we'd still welcome an intro to someone who is.
This page is for informational purposes only and does not constitute an offer to sell or solicitation of an offer to buy any security. Any offering will be made only through definitive documentation. Forward-looking statements regarding clinical and regulatory outcomes are subject to risk. Not medical advice.